Results 181 to 190 of about 187,939 (288)

IP3R2-Mediated Astrocytic Ca²⁺ Transients Are Critical to Sustain Modulatory Effects of Locomotion on Neurons in Mouse Somatosensory Cortex. [PDF]

Cells
Fernández de la Puebla M, Zhang X, Nagelhus EA, Bjørås M, Tang W.   +4 more
europepmc   +1 more source

Population pharmacokinetic modelling of amoxicillin in human breast milk—A contribution from the ConcePTION project

British Journal of Clinical Pharmacology, EarlyView.
Aims Amoxicillin, a widely used β‐lactam antibiotic, requires improved pharmacokinetic characterization during breastfeeding. This study used a population pharmacokinetic (PopPK) approach to model amoxicillin concentrations in breast milk, identify variability sources and estimate infant exposure, applying worst‐case scenarios.
Sarah Baklouti, Virginie Rigourd, Alice Panchaud, Hedvig Nordeng, Karel Allegaert, Pieter Annaert, Miao‐Chan Huang, Anaelle Monfort, Monia Guidi, Peggy Gandia   +9 more
wiley   +1 more source

Fate of Dissolved Methane from Ocean Floor Seeps. [PDF]

Environ Sci Technol
Nordam T, Dissanayake AL, Brakstad OG, Hakvåg S, Øverjordet IB, Litzler E, Nepstad R, Drews A, Röhrs J.   +8 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

A Classifier for Patient-Derived Colorectal Tumoroid Drug Sensitivity Using Confocal Imaging and Growth Rate Inhibition Metrics. [PDF]

Cancer Res Commun
Sakshaug BC, Haukaas TH, Folkesson E, Ringers C, Bwanika HCH, Bergstrøm IA, Sigfúsdóttir MS, Trøen HH, Sperstad SB, Stornes T, Klinkenberg G, Visnes T, Flobak Å.   +12 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle‐Aquitaine

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The French authorities mandated the use of secure prescriptions for pregabalin on May 2021. This study aimed to evaluate the impact of this measure on pregabalin use and misuse in Nouvelle‐Aquitaine, a southwestern French region with around six million inhabitants.
Maika Munech‐Herran, Véronique Moysan, Bruno Lescarret, Clément Mathieu, Antoine Pariente, Nicolas Rousselot   +5 more
wiley   +1 more source

Further Insight in the High Selectivity of Pb²⁺ Removal over Cd²⁺ in Natural and Dealuminated Rich-Clinoptilolite. [PDF]

Int J Mol Sci
Durán-Avendaño YS, Hernández NC, Ruiz-Salvador AR, Abatal M.   +3 more
europepmc   +1 more source

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations

British Journal of Clinical Pharmacology, EarlyView.
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić, Patrick Eustaquio, Elvira Meni Maria Gkrinia, Ivana Stević, Eugen Javor, Yun Wah Lam, Slobodan Janković, Dinko Vitezić   +7 more
wiley   +1 more source

GLU24/7 study: cardiometabolic health risk factors in night shift workers - protocol for a 2-year longitudinal study in an industrial setting in Norway. [PDF]

BMJ Open
Alsaedi S, Skogstad M, Haugen F.
europepmc   +1 more source